
Dan Krinsky, BS, MS, RPh, FAPhA, and Stefanie Ferreri, PharmD, BCACP, FAPhA, discuss new OTC product releases, recalls, and other updates pharmacists should be aware of.
Dan Krinsky, BS, MS, RPh, FAPhA, and Stefanie Ferreri, PharmD, BCACP, FAPhA, discuss new OTC product releases, recalls, and other updates pharmacists should be aware of.
Dan Krinsky, BS, MS, RPh, FAPhA, discusses the use of ChatGPT and artificial intelligence in assisting pharmacists for the management of OTC self-care products.
According to poison control data, many children aged 0 to 17 experience toxicity from over-the-counter analgesics like ibuprofen and acetaminophen.
Jasmine Cutler, PharmD, discusses the unique expertise pharmacists possess in order to counsel patients seeking any type of contraceptive product.
Lydia Newsom, PharmD, discuses how pharmacists can support patients using GLP-1s.
Discontinuing SSRIs or SNRIs during pregnancy did not lead to an increase in hospitalizations, outpatient visits, suicidal behavior, or sick leave use.
Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, clinical associate professor at University at Buffalo, discusses how pharmacists and patients view injectable contraception.
Control-IQ+ was associated with a greater reduction in glycated hemoglobin compared to a continuous glucose monitor alone.
Don Roosan, PharmD, PhD, joined Drug Topics to explore the future of ChatGPT in pharmacy practice and how AI is being used to manage patients’ medication regimens.
Jade Ranger, PharmD, co-owner and pharmacist at the Prescription Shoppe, discussed administering vaccines during the COVID-19 pandemic.
A recent study found that continuous glucose monitors could help improve patient comfort, reduce resource use, and improve outcomes.
Researchers explored how social media advertising of lifestyle drugs contributes to the normalization of use for semaglutide, testosterone, and sildenafil.
George Van Antwerp, MBA, discusses how the role of the pharmacist will evolve with the integration of precision medicine into the health systems setting.
In an Axios analysis of US Senate lobbying disclosures from the past year, researchers explored the ongoing trends of how certain industries distribute influence among legislators.
Jeffery Goad, PharmD, MPH, president of the National Foundation for Infectious Diseases, reflects on the COVID-19 pandemic 5 years later.
The new approval is an oral suspension for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy.
The top reported barriers to providing buprenorphine included regulatory and administrative, operational and attitudinal, and patient-related challenges.
On both an individual and societal level, researchers explored how social, cultural, and ethnic determinants impact the treatment and management of obesity.
As pharmacists move away from opioids in pain management, researchers present the use of supplemental OTC products to assist patients’ acute pain.
Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.
The most commonly reported symptoms of long COVID include neurological, muscular, respiratory, and psychological.
Using a novel pharmacy vulnerability index, researchers identified US regions at the most risk of becoming pharmacy deserts.
Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.
Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.
Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.
A new report from the American Economic Liberties Project presents the continued challenges pharmacies face since Congress’ failure to pass PBM reform at the end of 2024.
These findings challenge the common assumption that older adults might struggle to use more advance medical devices.
This year’s meeting will take place from March 21 to 24 in Nashville, Tennessee.
Additional data shows that an investigational drug, given every 4 months with Apretude, kept viral levels suppressed for patients who were already on stable treatment.
These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.